Centrient Pharmaceuticals Files Second Lawsuit Against Dalas Biotech
A second lawsuit has been filed by Centrient Pharmaceuticals India in the High Court of Delhi in New Delhi against Dalas Biotech for patent infringement.
As reported in an Oct. 18, 2019 press release from Centrient Pharmaceuticals, a second lawsuit has been filed by Centrient Pharmaceuticals India in the High Court of Delhi in New Delhi against Dalas Biotech for patent infringement.
The patent at the center of the litigation case covers an innovative enzyme that is used in the manufacture of amoxicillin trihydrate API. Through the patent litigation, Centrient is pursuing compensation for damages and a permanent injunction on the manufacture, use, sale in India, and exportation out of India of Dalas’ API that includes amoxicillin trihydrate produced by an enzyme.
“After having previously filed patent litigation against Dalas Biotech for patent infringement in India related to a process for the enzymatic manufacture of amoxicillin trihydrate, Centrient now furthers it enforcement actions by filing this second infringement action related to the innovative enzyme used in that process,” said Karl Rotthier, CEO at Centrient. “Centrient will continue to rigorously enforce its IP assets worldwide against any additional potential infringers in India or abroad.”
Source: Centrient
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
